Physician
Cordova Pain Specialists, PLLC
Cordova Pain Specialists, PLLC was paid $863K by Medicaid between Jan 2018 and Dec 2024, across 39 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 32% of everything it billed.
33Billing provider infoCORDOVA PAIN SPECIALISTS, PLLC
CORDOVA, TN 38016
CORDOVA, TN 38016
33aNPI1437565900assigned 07/06/2014
33bProvider typeAnesthesiology Physician
28Total paid$863K
24GClaims91,031
24DCodes billed39
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anesthesiology Physician providers in Tennessee
Rank by total paid#11 of 64
Median peer was paid$14K
This provider vs. median60×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,869 | $90K | |
| 2019 | 19,864 | $221K | |
| 2020 | 15,134 | $140K | |
| 2021 | 16,600 | $100K | |
| 2022 | 15,617 | $94K | |
| 2023 | 11,055 | $97K | |
| 2024incomplete | 7,892 | $120K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 32% | 14,959 | 12,633 | $276K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 10% | 3,581 | 3,168 | $88K |
| 96160 | 8.7% | 8,027 | 6,719 | $75K | |
| 96138 | 7.7% | 13,420 | 11,139 | $66K | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | 7.3% | 9,263 | 7,699 | $63K |
| 96132 | 6.4% | 6,715 | 5,640 | $55K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.6% | 10,007 | 7,992 | $49K |
| 96130 | 5.3% | 6,716 | 5,641 | $46K | |
| 96136 | 3.4% | 1,495 | 1,328 | $29K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2.3% | 5,376 | 4,261 | $19K |
| 96120 | 1.8% | 807 | 679 | $15K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.5% | 2,335 | 1,753 | $13K |
27 more codes
| 81025 | 1.3% | 2,820 | $11K | |
| 96127 | <1% | 1,465 | $8K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 131 | $8K |
| 93923 | <1% | 123 | $7K | |
| 96103 | <1% | 516 | $6K | |
| 96102 | <1% | 273 | $5K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 644 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 130 | $4K |
| 99454 | <1% | 148 | $3K | |
| 99457 | <1% | 145 | $2K | |
| 95923 | <1% | 50 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 71 | $2K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 229 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 31 | $766.18 |
| 95924 | <1% | 100 | $481.49 | |
| 81002 | <1% | 391 | $467.61 | |
| 99401 | <1% | 42 | $459.36 | |
| 93040 | <1% | 100 | $366.22 | |
| 99458 | <1% | 38 | $191.38 | |
| 99453 | <1% | 13 | $96.88 | |
| 81000 | <1% | 117 | $28.21 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 12 | $12.12 |
| 87641 | 0% | 36 | $0.00 | |
| 81003 | 0% | 404 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 37 | $0.00 |
| 87640 | 0% | 36 | $0.00 | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | 0% | 228 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILES, JOHN (AUTHORIZED OFFICIAL)